'Moderna will be a rare disease company,' CEO says, as mRNA company plots expansion in genetic diseases and eyes n-of-1 treatments
Just a few years ago, Moderna faced a chorus of doubts over whether its experimental mRNA technology would ever work well enough to become a medicine. After the $36 billion success of its Covid-19 vaccines, the question now becomes: What’s next?
The biotech’s answer over the past year has been “more of everything,” including an expansive infectious disease vaccine pipeline and developing personalized cancer vaccines with Merck. And now, early signs of success using the messenger molecule to make therapeutic proteins in the liver have Moderna ecstatic about yet another application for mRNA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.